Age Is Not a Limiting Factor in Interventional Radiotherapy (Brachytherapy) for Patients with Localized Cancer

Valentina Lancellotta, György Kovács, Luca Tagliaferri, Elisabetta Perrucci, Giuseppe Colloca, Vincenzo Valentini, Cynthia Aristei

Research output: Contribution to journalReview article

Abstract

This review examines the role of interventional radiotherapy (IRT otherwise known as brachytherapy) in cancer treatment for elderly patients. Despite their advanced age and associated comorbidities, elderly patients should receive definitive cancer therapies, including surgery and radiotherapy (RT). In fact, RT becomes first-line option for patients who are not eligible for surgery (due to comorbidities, anticoagulant drugs, and risk of disfigurement) or those who refuse it. It emerged from this review of the literature as effective, simple, safe, and comfortable and was associated with good local control, low toxicity rates, and excellent cosmesis and provided a cost benefit. IRT may be used as sole treatment for small cancers or as a useful adjunct to surgery or external beam radiotherapy (EBRT) in more advanced (or lymph node positive) cases, especially when the aim is local control with adequate preservation of normal tissue function. As palliative treatment, IRT preserves quality of life and/or improves survival. It is to be hoped that this review will serve as a helpful guide for members of multidisciplinary teams that are involved in treating elderly patients with cancer.

Original languageEnglish
Article number2178469
JournalBioMed Research International
Volume2018
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Brachytherapy
Radiotherapy
Surgery
Comorbidity
Neoplasms
Tissue Preservation
Oncology
Palliative Care
Anticoagulants
Cost-Benefit Analysis
Toxicity
Therapeutics
Lymph Nodes
Quality of Life
Tissue
Survival
Costs

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Age Is Not a Limiting Factor in Interventional Radiotherapy (Brachytherapy) for Patients with Localized Cancer. / Lancellotta, Valentina; Kovács, György; Tagliaferri, Luca; Perrucci, Elisabetta; Colloca, Giuseppe; Valentini, Vincenzo; Aristei, Cynthia.

In: BioMed Research International, Vol. 2018, 2178469, 01.01.2018.

Research output: Contribution to journalReview article

Lancellotta, Valentina ; Kovács, György ; Tagliaferri, Luca ; Perrucci, Elisabetta ; Colloca, Giuseppe ; Valentini, Vincenzo ; Aristei, Cynthia. / Age Is Not a Limiting Factor in Interventional Radiotherapy (Brachytherapy) for Patients with Localized Cancer. In: BioMed Research International. 2018 ; Vol. 2018.
@article{03f11192bb6b4a898bf0fcc70d4dfd17,
title = "Age Is Not a Limiting Factor in Interventional Radiotherapy (Brachytherapy) for Patients with Localized Cancer",
abstract = "This review examines the role of interventional radiotherapy (IRT otherwise known as brachytherapy) in cancer treatment for elderly patients. Despite their advanced age and associated comorbidities, elderly patients should receive definitive cancer therapies, including surgery and radiotherapy (RT). In fact, RT becomes first-line option for patients who are not eligible for surgery (due to comorbidities, anticoagulant drugs, and risk of disfigurement) or those who refuse it. It emerged from this review of the literature as effective, simple, safe, and comfortable and was associated with good local control, low toxicity rates, and excellent cosmesis and provided a cost benefit. IRT may be used as sole treatment for small cancers or as a useful adjunct to surgery or external beam radiotherapy (EBRT) in more advanced (or lymph node positive) cases, especially when the aim is local control with adequate preservation of normal tissue function. As palliative treatment, IRT preserves quality of life and/or improves survival. It is to be hoped that this review will serve as a helpful guide for members of multidisciplinary teams that are involved in treating elderly patients with cancer.",
author = "Valentina Lancellotta and Gy{\"o}rgy Kov{\'a}cs and Luca Tagliaferri and Elisabetta Perrucci and Giuseppe Colloca and Vincenzo Valentini and Cynthia Aristei",
year = "2018",
month = "1",
day = "1",
doi = "10.1155/2018/2178469",
language = "English",
volume = "2018",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Age Is Not a Limiting Factor in Interventional Radiotherapy (Brachytherapy) for Patients with Localized Cancer

AU - Lancellotta, Valentina

AU - Kovács, György

AU - Tagliaferri, Luca

AU - Perrucci, Elisabetta

AU - Colloca, Giuseppe

AU - Valentini, Vincenzo

AU - Aristei, Cynthia

PY - 2018/1/1

Y1 - 2018/1/1

N2 - This review examines the role of interventional radiotherapy (IRT otherwise known as brachytherapy) in cancer treatment for elderly patients. Despite their advanced age and associated comorbidities, elderly patients should receive definitive cancer therapies, including surgery and radiotherapy (RT). In fact, RT becomes first-line option for patients who are not eligible for surgery (due to comorbidities, anticoagulant drugs, and risk of disfigurement) or those who refuse it. It emerged from this review of the literature as effective, simple, safe, and comfortable and was associated with good local control, low toxicity rates, and excellent cosmesis and provided a cost benefit. IRT may be used as sole treatment for small cancers or as a useful adjunct to surgery or external beam radiotherapy (EBRT) in more advanced (or lymph node positive) cases, especially when the aim is local control with adequate preservation of normal tissue function. As palliative treatment, IRT preserves quality of life and/or improves survival. It is to be hoped that this review will serve as a helpful guide for members of multidisciplinary teams that are involved in treating elderly patients with cancer.

AB - This review examines the role of interventional radiotherapy (IRT otherwise known as brachytherapy) in cancer treatment for elderly patients. Despite their advanced age and associated comorbidities, elderly patients should receive definitive cancer therapies, including surgery and radiotherapy (RT). In fact, RT becomes first-line option for patients who are not eligible for surgery (due to comorbidities, anticoagulant drugs, and risk of disfigurement) or those who refuse it. It emerged from this review of the literature as effective, simple, safe, and comfortable and was associated with good local control, low toxicity rates, and excellent cosmesis and provided a cost benefit. IRT may be used as sole treatment for small cancers or as a useful adjunct to surgery or external beam radiotherapy (EBRT) in more advanced (or lymph node positive) cases, especially when the aim is local control with adequate preservation of normal tissue function. As palliative treatment, IRT preserves quality of life and/or improves survival. It is to be hoped that this review will serve as a helpful guide for members of multidisciplinary teams that are involved in treating elderly patients with cancer.

UR - http://www.scopus.com/inward/record.url?scp=85041700045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041700045&partnerID=8YFLogxK

U2 - 10.1155/2018/2178469

DO - 10.1155/2018/2178469

M3 - Review article

C2 - 29581964

AN - SCOPUS:85041700045

VL - 2018

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 2178469

ER -